{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypothyroidism/management/overt-hypothyroidism-non-pregnant/","result":{"pageContext":{"chapter":{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)","depth":2,"htmlHeader":"<!-- begin field 9adebf78-d4ba-4ce8-bb4d-2aaf685434c4 --><h2>Scenario: Overt hypothyroidism (non-pregnant)</h2><!-- end field 9adebf78-d4ba-4ce8-bb4d-2aaf685434c4 -->","summary":"Covers the management of overt hypothyroidism and criteria for referral in primary care.","htmlStringContent":"<!-- begin item 0dd63190-9cd6-4384-9cad-13bd47fb1e20 --><!-- begin field c3cee0f3-5cc5-4f98-a376-acbc0156466e --><p>From age 18 years onwards.</p><!-- end field c3cee0f3-5cc5-4f98-a376-acbc0156466e --><!-- end item 0dd63190-9cd6-4384-9cad-13bd47fb1e20 -->","topic":{"id":"f1d76bc1-c8dd-515b-a709-48c70c829658","topicId":"ebfc5032-6653-4b11-895c-5080f933e861","topicName":"Hypothyroidism","slug":"hypothyroidism","lastRevised":"Last revised in August 2020","chapters":[{"id":"cf0a606b-f582-5671-a84d-a1a3a12b7180","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"795eb9d9-4e15-51f6-81f4-7cc1b69ca74e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8d7a846-dfa6-5db5-ba95-fb161fd48c6e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d8567cc1-0642-5e9e-ad6c-8ca4abf5fa6e","slug":"changes","fullItemName":"Changes"},{"id":"c5e99cd1-e0c7-5efd-84bb-15bac6122b1d","slug":"update","fullItemName":"Update"}]},{"id":"2b8464ae-3182-517a-85be-6acc656616c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"17d5ebf3-bdca-50d2-a4f5-245d191f4973","slug":"goals","fullItemName":"Goals"},{"id":"9162c6a3-edc4-5319-9418-04b2cb656ce6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ae5c1d9-638e-52fa-b738-9561cd11b0ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fec82ae-e144-56a7-b1e8-8744c35e227e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"610f052f-83a2-5b06-b5e6-4aa272ef73a6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a578bde3-0d84-54f7-814d-18ed38e6038a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4b8f382f-673d-5804-8291-438e21e32790","slug":"definition","fullItemName":"Definition"},{"id":"ef0d96cd-207c-5814-93cf-c96870e2251d","slug":"causes","fullItemName":"Causes"},{"id":"09adb285-1d01-592a-9443-295b45c7d78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications"},{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cfe582c4-479a-5d44-b893-ac46a1a80b29","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6884c3db-6165-566b-a4ca-3e933de77714","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"42799fb8-7252-541e-9af1-27ebc28710b7","slug":"assessment","fullItemName":"Assessment"},{"id":"e850b740-b6cf-55a7-aed8-7372b7f13b05","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"d817ab4c-e7a3-582a-94fa-fcffd9c2d4f6","slug":"screening","fullItemName":"Screening"}]},{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","fullItemName":"Management","slug":"management","subChapters":[{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)"},{"id":"e358d249-a2f3-5a06-b301-2119af9ae164","slug":"subclinical-hypothyroidism-non-pregnant","fullItemName":"Scenario: Subclinical hypothyroidism (non-pregnant)"},{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant"},{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum"}]},{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine"}]},{"id":"2aaf1754-ba79-5b47-b2a5-74fe8f6af4da","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7669c894-3a85-55c7-b689-cb4b710a838a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"840d7de5-8c31-5696-9de6-c80ce1bbfec7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"299c20bf-2a22-5681-99ad-5f02f1395969","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd3df39b-4a5c-5416-af8d-dcdbf46bd255","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a88d4431-778a-5793-9557-9f806339a95b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1987302d-f600-55e0-a528-d3486c49048e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a49e5d2f-75e4-5219-a4d6-fd4a5595a776","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"8698eb0b-3dd9-5c8f-808f-77f1d683bffc","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 93039dbf-eb64-43c3-b8ff-26eb7d30f33d --><h3>How should I manage a person with overt hypothyroidism (non-pregnant)?</h3><!-- end field 93039dbf-eb64-43c3-b8ff-26eb7d30f33d -->","summary":null,"htmlStringContent":"<!-- begin item 184370b7-269a-43fb-8889-eace472d2a3c --><!-- begin field 0ad63a53-8d7b-44bc-804e-8d86794c204b --><p><strong>If a person has confirmed <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/diagnosis/assessment/\">overt hypothyroidism</a>:</strong></p><ul><li><strong>Arrange emergency admission</strong> if a serious <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/background-information/complications/\">complication</a> such as myxoedema coma is suspected.</li><li><strong>Arrange urgent referral to an endocrinologist </strong>for specialist assessment of the underlying cause, if <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/background-information/definition/\">secondary hypothyroidism</a> is suspected.</li><li><strong>Arrange referral or discuss with an endocrinologist, </strong>the urgency depending on clinical judgement, if the person:<ul><li>Has suspected <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/diagnosis/assessment/\">subacute thyroiditis</a>.</li><li>Has a goitre, nodule, or structural change in the thyroid gland. If malignancy is suspected, refer using a suspected cancer pathway. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/neck-lump/\">Neck lump</a> and <a class=\"topic-reference external-reference\" href=\"/topics/head-neck-cancers-recognition-referral/\">Head and neck cancers - recognition and referral</a> for more information.</li><li>Has suspected associated endocrine disease, such as Addison's disease.<ul><li>Do not start thyroid hormone replacement before specialist glucocorticoid replacement in suspected adrenal failure, as this can precipitate an adrenal crisis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/addisons-disease/\">Addison&#39;s disease</a> for more information.</li></ul></li><li>Is female and is planning a pregnancy. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/management/preconception-or-pregnant/\">Scenario: Preconception or pregnant</a> in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/management/\">Management</a> for more information.</li><li>Has atypical or <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/diagnosis/assessment/#interpreting-thyroid-function-tests\">difficult to interpret</a> thyroid function tests (TFTs), such as a low thyroid-stimulating hormone (TSH) with low free thyroxine (FT4) level.</li><li>Has a suspected underlying cause of hypothyroidism, such as <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/background-information/causes/\">drug treatment</a> with amiodarone or lithium.</li></ul></li><li><strong>Offer advice on sources of information and support, such as:</strong><ul><li>The British Thyroid Foundation leaflets <a data-hyperlink-id=\"91d543bc-b153-42fd-bb36-ab3c00b140a1\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=736ef4b2-e97f-472b-afc9-0b1f16b65d2a\" target=\"_blank\">Your guide to hypothyroidism</a> and <a data-hyperlink-id=\"fcd9bc67-61af-48f5-987e-ab5000991677\" href=\"https://www.btf-thyroid.org/Handlers/Download.ashx?IDMF=98f12be4-fa91-402a-847a-a3ae22fa33bd\" target=\"_blank\">Your guide to thyroid function tests</a>.</li><li>The NHS information leaflet <a data-hyperlink-id=\"8f1cd9f0-60a0-4949-8781-ab3c00b140be\" href=\"https://www.nhs.uk/conditions/underactive-thyroid-hypothyroidism/\" target=\"_blank\">Underactive thyroid (hypothyroidism)</a>.</li><li>The patient information leaflet <a data-hyperlink-id=\"e096dcc6-f415-4774-992d-ab3c00b140d9\" href=\"https://patient.info/hormones/thyroid-and-parathyroid-glands/underactive-thyroid-gland-hypothyroidism\" target=\"_blank\">Underactive thyroid gland. Hypothyroidism</a> available on the <a data-hyperlink-id=\"a53ab994-aa1f-4a5e-80c4-ab3c00b140eb\" href=\"https://patient.info/\" target=\"_blank\">www.patient.info</a> website.</li></ul></li><li><strong>If specialist referral is not needed,</strong> <strong>treat overt primary hypothyroidism with levothyroxine (LT4) monotherapy.</strong><ul><li>Advise the person to take LT4 medication on an empty stomach in the morning before other food or medication.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/levothyroxine/#initiation-titration\">Initiation and titration</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/\">Prescribing information</a> for detailed information on the initiation and titration of LT4 therapy.</li><li>Do <em>not</em> prescribe liothyronine (LT3) alone, combination therapy (LT4 and LT3), or natural thyroid extracts in primary care.</li><li>Advise that symptoms may lag behind treatment changes for several weeks or months. In addition, even if TFTs are within normal range, changes in LT4 therapy may improve symptoms for some people.</li></ul></li><li>Review the person and recheck TSH levels every 3 months after initiation of LT4 therapy and adjust the dose according to symptoms and TFT results. Consider checking FT4 in addition if the person has ongoing symptoms on treatment.<ul><li>Aim to resolve <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/diagnosis/diagnosis/\">symptoms and signs</a> of hypothyroidism.</li><li>Aim to maintain serum TSH and FT4 levels within or close to the normal reference range.</li><li>If symptoms persist, consider adjusting the dose of LT4 further to achieve optimal wellbeing, taking care to avoid over-treatment.</li></ul></li><li>If a person has suspected <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/levothyroxine/#adverse-effects\">adverse effects</a> or feels more unwell after starting LT4 therapy:<ul><li>Consider possible under- or over-treatment with LT4. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/background-information/complications/\">Complications</a> for more information on possible consequences of under-treatment. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hyperthyroidism/\">Hyperthyroidism</a> for more information on possible consequences of over-treatment.</li><li>Consider whether associated endocrine disease such as Addison's disease is a possibility, and arrange specialist endocrinology referral depending on clinical judgement. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/addisons-disease/\">Addison&#39;s disease</a> for more information.</li></ul></li><li>Once the TSH level is stable (2 similar measurements within the reference range 3 months apart), check TSH annually.<ul><li>Recheck serum lipids if needed, to see if they have improved or whether management for dyslipidaemia is needed. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> and <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a> for more information.</li></ul></li></ul></li><li><strong>If TFTs remain abnormal or the person has persistent symptoms despite adequate or escalating LT4 doses:</strong><ul><li>Assess for any possible causes and manage appropriately. These include:<ul><li>Non-compliance with prescribed LT4 treatment.</li><li>Drug interactions of LT4 treatment with other medication that may reduce LT4 absorption or increase LT4 requirements, including multivitamins and other over-the-counter medication. Advise the person to leave an interval of four hours between taking LT4 and the potentially interfering drug, if possible. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/levothyroxine/#drug-interactions\">Drug interactions</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/prescribing-information/\">Prescribing information</a> for more information on potential drug interactions.</li><li>Gastrointestinal conditions causing malabsorption such as coeliac disease, <em>Helicobacter pylori</em> gastritis, atrophic gastritis/pernicious anaemia, giardiasis, and inflammatory bowel disease, which may reduce absorption of LT4 in the gut.</li><li>Simultaneous intake of LT4 with food and drink such as milk, coffee, grapefruit juice, soya products, and papaya which can impair absorption of LT4.</li><li>Weight gain and pregnancy which may increase LT4 requirements.</li></ul></li><li>Adjust the dose of LT4 therapy as appropriate if a contributing factor is identified and is optimally managed.</li></ul></li><li><strong>Consider referral to an endocrinologist if a person is taking:</strong><ul><li>Adequate or escalating LT4 doses and the TSH level is persistently raised, and underlying causes have been excluded or managed.</li><li>Adequate or escalating LT4 doses and <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/diagnosis/diagnosis/\">symptoms</a> of hypothyroidism persist, and <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/diagnosis/differential-diagnosis/\">alternative causes</a> for symptoms have been excluded.</li><li>Combination therapy or LT3 monotherapy on specialist advice with uncertain benefits, and a switch to LT4 is being considered.</li></ul></li></ul><!-- end field 0ad63a53-8d7b-44bc-804e-8d86794c204b --><!-- end item 184370b7-269a-43fb-8889-eace472d2a3c -->","subChapters":[{"id":"20b3ae8c-9e41-573b-9d49-fb980e94291a","slug":"basis-for-recommendation-baa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 140a9d89-0f49-4d6b-9ca4-79fe0910a939 --><h4>Basis for recommendation</h4><!-- end field 140a9d89-0f49-4d6b-9ca4-79fe0910a939 -->","summary":null,"htmlStringContent":"<!-- begin item baaa280c-2e3c-47d1-bb51-102ce7a49f63 --><!-- begin field 909d2b79-b2cc-4c41-9fa0-361bc44fc622 --><p>The recommendations on management of overt hypothyroidism are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2017</a>] and <em>Thyroid disease: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>], the British Thyroid Association (BTA) position statement <em>Management of primary hypothyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>] and BTA publications <em>Information for members on prescribing liothyronine (L-T3)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016a</a>] and <em>Switching your patient from liothyronine (L-T3) to levothyroxine (L-T4): answering GP's frequently asked questions</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016b</a>]; the European Thyroid Association (ETA) publications <em>The use of L-T4 + L-T3 in the treatment of hypothyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Wiersinga et al, 2012</a>], <em>Management of subclinical hypothyroidism </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>], and <em>Guidelines on the diagnosis and management of central hypothyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Persani, 2018</a>]; the American Thyroid Association (ATA) publications <em>Guidelines for the treatment of hypothyroidism</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>] and <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>]; and expert opinion in review articles on hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Gaitonde et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>], subclinical hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Bekkering, 2019</a>], treatment-refractory hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">McNally, 2019</a>], and expert opinion in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>].</p><h5>Arranging emergency admission if suspected serious complication</h5><ul><li>The recommendation to arrange emergency admission if a serious complication such as myxoedema coma is suspected is based on expert option in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Weetman, 2010</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Gaitonde et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].<ul><li>Myxoedema coma may be a life-threatening event and is a medical emergency.</li></ul></li></ul><h5>Arranging urgent endocrinology referral if suspected secondary hypothyroidism</h5><ul><li>The recommendation to urgently refer all people with suspected secondary hypothyroidism for further specialist assessment is extrapolated from the ATA publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>] and the ETA guidelines on central hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Persani, 2018</a>]. </li><li>The ATA publication notes that people with secondary hypothyroidism taking levothyroxine (LT4) therapy can potentially be exposed to adverse effects of excess or inadequate thyroid hormone, without 'the usual signal from an abnormal thyroid-stimulating hormone (TSH)'.</li><li>The ETA guidelines advise on the need to exclude co-existent central adrenal insufficiency, which requires specialist assessment and interpretation of results.</li></ul><h5>Arranging specialist referral</h5><ul><li>The recommendations on who to refer to an endocrinology specialist are largely based on the ETA publications on subclinical hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>] and central hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Persani, 2018</a>], the ATA guideline on pregnancy and the postpartum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Gaitonde et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].<ul><li>The recommendation to arrange referral if thyroid cancer is suspected is based on the NICE clinical guidelines on suspected cancer [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2017</a>] and thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>].</li><li>If co-existent central adrenal insufficiency cannot be ruled out or is not yet treated, LT4 replacement must be started after glucocorticoid therapy in order to prevent the possible precipitation of an adrenal crisis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Persani, 2018</a>].</li><li>The recommendation to refer if a woman is planning a pregnancy is extrapolated from the ATA guideline on pregnancy and the postpartum [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>The recommendation to refer if there are atypical or difficult to interpret thyroid function tests (TFTs) is based on the fact these may indicate a TSH-secreting pituitary adenoma, end-organ resistance to thyroid hormones, or other thyroid hormone metabolism disorder which requires specialist assessment and diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li></ul></li></ul><h5>Offering sources of information and support</h5><ul><li>This recommendation is based on the NICE clinical guideline on thyroid disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>], and is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Treating primary hypothyroidism with LT4 monotherapy</h5><ul><li>The recommendation to offer LT4 monotherapy first-line to all adults with primary hypothyroidism and arrange follow-up monitoring is largely based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>]. It is supported by the BTA position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>], the ATA guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].<ul><li>The NICE guideline based its recommendations on qualitative studies together with the experience and expertise of the guideline development group.<ul><li>It states that a high starting dose of LT4 produced more rapid improvements in quality of life than a lower starting dose followed by titration, in adults unless contraindicated.</li><li>It recommends using a cut-off of 65 years when deciding on initial LT4 treatment doses and regimens, as adults over 65 years of age are more likely to have cardiovascular disease, and this age cut-off is used in studies when defining older adults.</li><li>It recommends the goals of treatment are to relieve symptoms and maintain TFTs within or close to the reference range.</li><li>It included information for patients that symptoms may lag behind treatment changes for several weeks or months, and even if a person is asymptomatic, treatment may be recommended to reduce the risk of long-term complications.</li><li>It noted that LT4 is often taken incorrectly leading to potential suboptimal treatment of hypothyroidism.</li><li>It recommends if symptoms of hypothyroidism persist, consider adjusting the dose of LT4 further to achieve optimal wellbeing, taking care to avoid over-treatment. This is based on the fact that some people may still have troublesome symptoms even with TSH levels in the reference range, and changes in LT4 dose may improve symptoms for some people.</li><li>The recommendations on the frequency of repeating TFT monitoring and the definition of a stable TSH are based on the experience and expertise of the NICE guideline development group.</li></ul></li><li>The recommendations on the use of LT4 monotherapy are supported by the ATA guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>].<ul><li>These found moderate-quality evidence that LT4 is the first-line treatment of choice due to its efficacy in resolving hypothyroidism symptoms, long-term experience of benefit, favourable adverse effect profile, ease of administration, good intestinal absorption, long serum half-life, and low cost.</li><li>They recommend the same treatment goals as NICE, but note that assessment of symptoms alone lack sensitivity and specificity.</li><li>They recommend taking LT4 therapy 60 minutes before breakfast for optimal consistent absorption of LT4.</li></ul></li><li>The BTA position statement also supports the use of LT4 monotherapy first-line [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>].<ul><li>It states the management of primary hypothyroidism with LT4 is simple, effective, and safe, and most people report improved wellbeing following starting treatment.</li><li>It defines the goal of treatment as to manage physical and psychological features of hypothyroidism and to normalize TSH.</li></ul></li><li>The recommendation to recheck and manage lipid results is extrapolated from the ETA guideline on subclinical hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>].</li><li>Expert opinion in a review article notes the risks of LT4 overtreatment (iatrogenic subclinical or overt hyperthyroidism) which may increase the risk of atrial fibrillation and/or osteoporosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li></ul></li></ul><h5>Not prescribing liothyronine (LT3), combination therapy (LT4 and LT3), or natural thyroid extracts in primary care</h5><ul><li>The recommendation not to prescribe other thyroid hormones or thyroid extracts in primary care is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>], the BTA position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>], two BTA publications for endocrinologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016a</a>] and GPs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016b</a>], the ETA publication on combination therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Wiersinga et al, 2012</a>], the ATA publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Hennessey, 2018</a>].<ul><li>The NICE clinical guideline advises not to routinely offer LT3 for primary hypothyroidism, either alone or in combination with LT4, or natural thyroid extracts, as there is insufficient evidence that these preparations offer health benefits over LT4 monotherapy, and their long-term adverse effect profile is uncertain. In addition, NICE notes that natural thyroid extract is unlicensed for use in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">NICE, 2019</a>].<ul><li>NICE based its findings on a review of seven randomized controlled trials (RCTs) which found no additional health benefits over LT4 monotherapy, and found these treatments were more expensive. </li><li>It noted there may be small benefits in some quality of life domains in small subgroups of people who continue to feel unwell on LT4 monotherapy, and it noted anecdotal evidence from the guideline development group.</li></ul></li><li>The ETA publication found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Wiersinga et al, 2012</a>]:<ul><li>Data suggest possible symptoms of hypothyroidism persist in 5–10% of LT4-treated people with hypothyroidism who have normal TSH levels. It states that one explanation may be inadequacy of LT4 treatment to restore physiological thyroxine (T4) and triiodothyronine (T3) concentrations in serum and tissues (among other possibilities).</li><li>A meta-analysis of RCTs found LT4 and LT3 combination therapy was not superior to LT4 monotherapy when outcomes of quality of life, mood, symptoms, and cognition were assessed. It found, however, marked heterogeneity among the included studies regarding sample size, recruitment policy, study design, dose ratios of combination therapy, and duration of intervention.</li><li>There was insufficient evidence that LT4 and LT3 combination therapy is better than LT4 monotherapy, and it recommended that LT4 monotherapy remains the standard treatment of hypothyroidism.</li><li>That combination therapy may be considered and initiated by endocrinology specialists as an experimental approach in people who are compliant with LT4 therapy, who have persistent symptoms despite serum TSH values being within the reference range, if associated autoimmune conditions have been excluded. It advises that specialist combination treatment should be discontinued if there is no improvement in symptoms after 3 months.</li><li>A lack of long-term safety data for T3 therapy, and that a serum increase in FT3 may provoke cardiac arrhythmias in susceptible people.</li></ul></li><li>The ATA publication found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>]:<ul><li>No consistently strong evidence for the use of combination therapy or thyroid extract therapy over LT4 monotherapy in improving health outcomes.</li><li>Conflicting results of benefits from RCTs comparing combination therapy to LT4 monotherapy, and a lack of long-term safety outcome data.</li><li>On reviewing the evidence that it recommended against the routine use of combination therapy or thyroid extract therapy over LT4 monotherapy.</li><li>Potential safety concerns related to the use of thyroid extracts, such as the presence of supra-physiologic serum T3 levels, and a lack of long-term safety outcome data.</li></ul></li><li>The BTA position paper found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>]:<ul><li>On review of the ETA and ATA guidelines, it did not support the routine use of LT4 and LT3 combination therapy due to insufficient evidence from controlled trials, a lack of long-term LT3 safety data, and the lack of available LT3 formulations that mirror natural physiology.</li><li>Insufficient evidence that combination treatment is superior to LT4 monotherapy.</li><li>Combination treatment may be started in exceptional circumstances and only initiated by an endocrinologist as an experimental approach.</li><li>Insufficient evidence to support routine use of combination therapy and a lack of long-term safety data, and noted that combination treatment may be potentially harmful.</li><li>That future RCTs will be of value, especially on the use of combination therapy in people with specified genetic or clinical characteristics.</li><li>That on reviewing the evidence, routine use of LT3 monotherapy or thyroid extracts was not recommended.</li></ul></li><li>A BTA publication gives advice for endocrinologists considering switching patients from LT3 to LT4 therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016a</a>]:<ul><li>It does not support the sudden withdrawal of LT3 therapy, and notes the decision to continue or stop LT3 should be based on clinical need.</li><li>In people where it is agreed to switch from combination LT3 and LT4 therapy or from LT3 monotherapy to LT4 monotherapy, it advises the transition should be made cautiously and gradually aiming to avoid under- or over-replacement with thyroid hormones.</li></ul></li><li>A BTA publication gives advice for GPs on switching LT3 to LT4 therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016b</a>]:<ul><li>It advises that people with uncertain benefits on LT3 therapy should be considered for a switch to LT4 therapy, and advice should be sought from an endocrinologist on how this can be safely done.</li><li>It states that patients should be advised that a change in thyroid hormone treatment can result in some instability in thyroid status.</li></ul></li></ul></li></ul><h5>Managing treatment-refractory hypothyroidism</h5><ul><li>The information on possible causes for treatment-refractory hypothyroidism is based on the ETA publication on subclinical hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>], the ATA publication on hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">McNally, 2019</a>].<ul><li>Expert opinion in review articles notes that poor compliance is the most common reason for unusually high thyroid hormone dose requirements [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>The ATA publication recommends leaving a four-hour interval between taking LT4 therapy and other potentially interacting medications. This approach is also supported by expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Bekkering, 2019</a>].</li><li>The ATA publication recommends assessing the person for malabsorption conditions if LT4 dose requirements are higher than expected [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>]. This approach is supported by the ETA publication on subclinical hypothryoidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Pearce, 2013</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>The information that some food and drink can impair LT4 absorption is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>The information about the implications of weight gain and pregnancy on LT4 requirements is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">McNally, 2019</a>].</li></ul></li><li>The recommendation to adjust the dose of LT4 therapy as appropriate if a contributing factor is identified and is optimally managed is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">McNally, 2019</a>], and is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Considering referral for treatment-refractory hypothyroidism</h5><ul><li>The recommendation to exclude alternative causes and consider specialist referral for persistent symptoms or abnormal TFTs is based on the ETA publication on combination therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Wiersinga et al, 2012</a>], the ATA publication on hypothyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>], the BTA position statement [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>], the BTA publication for endocrinologists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016a</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">McNally, 2019</a>].<ul><li>The ETA publication found data suggesting possible symptoms of hypothyroidism persist in 5–10% of people on adequate LT4 treatment, who have normal TSH levels [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Wiersinga et al, 2012</a>].</li><li>The ATA publication found low-quality evidence that in a minority of people with hypothyroidism with normal TSH values, 'a suboptimal health status' of unclear cause is reported. It highlights the importance of assessing for alternative causes in such cases [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Jonklaas et al, 2014</a>].</li><li>The recommendation to consider endocrinology referral if a person has a persistently raised TSH despite adequate or escalating LT4 treatment doses is based on expert opinion in a review article, which notes that this approach can increase the risk for prolonged exposure to subtherapeutic doses of LT4 with associated adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>].</li><li>Expert opinion in review articles notes that a person may have concurrent autoimmune disease or possible inadequate thyroid hormone concentration at the tissue level causing ongoing symptoms, which requires specialist assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Chaker, 2017</a>].</li><li>An endocrinologist may perform LT4 absorption challenge tests to differentiate true malabsorption from non-adherence to treatment, and additional blood testing may be arranged to exclude TSH assay interference or resistance to thyroid hormone. This approach is preferable to ongoing escalation of LT4 doses in primary care which may risk iatrogenic hyperthyroidism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Centanni, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">McNally, 2019</a>].</li><li>The BTA publication advises that people with uncertain benefits on LT3 therapy should be considered for a switch to LT4 therapy, and advice should be sought from an endocrinologist on how this can be safely done [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Okosieme, 2015</a>].</li><li>The BTA publication for endocrinologists notes the need for a gradual switch with the aim to avoid over- or under-replacement of thyroid hormone, and recommends careful monitoring of the person by an endocrinologist during the transition period [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">BTA, 2016a</a>].</li></ul></li></ul><!-- end field 909d2b79-b2cc-4c41-9fa0-361bc44fc622 --><!-- end item baaa280c-2e3c-47d1-bb51-102ce7a49f63 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}